7-Bromo-2-chloroquinazoline

Catalog No.: 
ACICXD684
CAS No.: 
953039-66-2
Molecular Formula: 
C8H4BrClN2
Molecular Weight: 
243.49
7-Bromo-2-chloroquinazoline structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$58.00In stockIn stock
5g95%$208.00In stockIn stock
10g95%$415.00In stockIn stock
25g95%$1032.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name7-Bromo-2-chloroquinazoline
IUPAC Name7-bromo-2-chloroquinazoline
MDL No.MFCD11040175
Molecular FormulaC8H4BrClN2
Molecular Weight243.49
SMILESBrC1=CC=C2C(=C1)N=C(N=C2)Cl
InChI KeyLEVIQMAFISIVMA-UHFFFAOYSA-N
SynonymAC-26955 | CS-W009223 | DS-10766 | DTXSID50672195 | FT-0648796 | LEVIQMAFISIVMA-UHFFFAOYSA-N | BCP10060 | MFCD11040175 | Z1269187846 | SY023979 | AMY15324 | SCHEMBL1633846 | EN300-3259744 | AKOS015835909 | 7-BROMO-2-CHLOROQUINAZOLINE | PB10831
CAS No.953039-66-2
PubChem CID45790052

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACICXD684 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACEPQR285 route compound structure diagram
    ACEPQR285953039-65-1In Stock
  4. Then
  5. ACICXD684 route product structure diagram
    ACICXD684953039-66-2In Stock
Inquiry

2. ACICXD684 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACICXD684 route product structure diagram
    ACICXD684953039-66-2In Stock
Inquiry

3. ACICXD684 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACICXD684 route product structure diagram
    ACICXD684953039-66-2In Stock
Inquiry

Comments (0)